Can‑Fite BioPharma’s 1‑for‑3,000 Reverse Split: Boosting Perception Amid Earnings Struggles
Can‑Fite BioPharma’s 1‑for‑3,000 reverse split, low 52‑week price, and ongoing R&D drive investor interest in its biopharma future.
2 minutes to read
Can-Fite BioPharma Ltd
Can-Fite BioPharma Secures FDA Approval for Namodenoson, Boosting Hope for Autoimmune and Cancer Treatments
Can-Fite BioPharma has secured FDA approval for the compassionate use of its asset Namodenoson, a potential breakthrough for patients with autoimmune-inflammatory diseases and cancer.
2 minutes to read